Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections

Current Medical Research and Opinion

Volumn 21, Issue 5, 2005, Pages 785-794

  Edwards, Steven J ^a   Emmas, Cathy E ^a   Campbell, Helen E ^b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Imipenem; Infection; Meropenem; Meta analysis; Systematic review

Indexed keywords

CILASTATIN PLUS IMIPENEM; MEROPENEM;

ADOLESCENT; ADULT; ANTIMICROBIAL THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; EMBASE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; MEDLINE; META ANALYSIS; MORTALITY; NAUSEA; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEIZURE; SYSTEMATIC REVIEW; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CILASTATIN; DRUG THERAPY, COMBINATION; HUMANS; IMIPENEM; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RISK; THIENAMYCINS;

EID: 18844420245     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X46223     Document Type: Review

References (55)

1. Zhanel GG, Simor AE, Vercaigne L. Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse events. Can J Infect Dis 1998;9:215-8
2. Calandra G, Lydick E, Carrigan J. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988;84:911-8
3. Wong VK, Wright Jr HT, Ross LA, et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis 1991;10:122-5
4. Wang C, Calandra GB, Aziz MA, Brown KR. Efficacy and safety of imipenem/cilastatin: a review of world-wide clinical experience. Rev Infect Dis 1985;7(Suppl 3):S528-36
5. Meropenem Summary of Product Characteristics (January 2004)
6. Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5000 patients treated with meropenem. Scand J Infect Dis 1999;31:3-10
7. Ambrose PG, Quintiliani R, Richardson MA. Differentiating carbapenems: imipenem/cilastatin and meropenem. Today's Therapeutic Trends 1998;16:7-21
8. Mouton JW, Touw DJ, Horrevorts AM, Vinks AATMM. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000;39:185-201
9. Hurst M, Lamb HM. Meropenem: a review of its use in patients in intensive care. Drugs 2000;59:653-80
10. Chalmers TC, Celano P, Sacks HS, Smith Jr H. Bias in treatment assignment in controlled clinical trials. New Engl J Med 1983;309:1358-61
11. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. J Am Med Assoc 1995;273:408-12
12. Deeks J, Higgins JPT, Altman D. Analysing and presenting results. In: Alderson P, Green S, Higgins J, editors. Cochrane reviewers' handbook 4.2.1, section 8. Chichester. John Wiley & Sons Ltd; 2004. p. 68-139
13. Review Manager (RevMan) [computer program] version 4.2 for Windows. Oxford: The Cochrane collaboration; 2003
14. StatsDirect Ltd. StatsDirect statistical software. http://www. statsdirect.com. StatsDirect Ltd, England, 2002
15. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine, 2nd ed. Oxford: Oxford University Press; 2000
16. Hara K, Kono S, Koga H, et al. Dose finding study on meropenem in bacterial pneumonia. Chemother (Tokyo) 1992;40(Suppl):447-63
17. Hara K, Kono S, Koga H, et al. A comparative study of meropenem and imipenem/cilastatin sodium in chronic respiratory tract infections. Chemother 1992;40:1426-50
18. Kumazawa J, Matsumoto T, Tanaka M, et al. Dose finding study of meropenem in complicated urinary tract infection. Chemother 1992;40(Suppl 1):631-45
19. Kumazawa J, Matsumoto T, Tanaka M, et al. Clinical evaluation of meropenem for the treatment of complicated urinary tract infections - a double-blind controlled study using imipenem/cilastatin. Nishinihon J Urol 1992;54:954-69
20. Sartoretti C, Attinger B, Largiader F, Geroulanos ST. Meropenem versus imipenem in the treatment of abdominal infections. Abstract No. 1583, 32nd interscience conference on antimicrobial agents and chemotherapy, American Society for Microbiology, Washington (DC), 1992
21. Kanellakopoulou K, Giamarellou H, Papadothomakos P, et al. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 1993;12:449-53
22. Brismar B, Malmborg AS, Tunevall G, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrobial Chemother 1995;35:139-48
23. Cox C, Hollo way WJ, Geckler RW. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalised patients. Clin Infect Dis 1995;21:86-92
24. Geroulanos SJ. Meropenem versus imipenem/cilastatin in intra-abdorninal infections requiring surgery. J Antimicrobial Chemother 1995;36(Suppl A):191-205
25. Hamacher J, Vogel F, Lichey J, et al. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients - a comparison of meropenem and imipenem/cilastatin. J Antimicrob Chemother 1995;36(Suppl A):121-33
26. Morandini GC. Clinical efficacy, tolerance and antibacterial activity of intramuscular meropenem in non-nosocomial lower respiratory tract infections. A comparative multicentre hospital study. Minerva Pneumologica 1995;34:45-54
27. Nord CE, Brismar B, Ekland A-E. Immune response in patients with intra-abdominal infections treated with imipenem/cilastatin or meropenem. Can J Infect Dis 1995;6(Suppl C):426C
28. Tallarigo C, Comunale L, Baldassarre R, Poletti G. Studio multicentrico comparative su meropenem vs imipenem nel trattamento intramuscolare delle infezioni urinary ospedaliere. Minerva Urologica e Nefrologica 1995;4:147-56
29. Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalised patients. J Antimicrob Chemother 1996;38;523-37
30. Vogel F, Lichey J, Kohl FV. Treatment of acute bacterial exacerbations of COPD in hospitalised patients - meropenem vs imipenem/cilastatin. Antiinfect Drugs Chemother 1996;14:83
31. Garau J, Blanquer J, Cobo L, et al. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbl Infect Dis 1997;16:789-96
32. Hartenauer U, Kljucar S, Bender H-J, et al. Meropenem versus imipenem/cilastatin for the treatment of serious bacterial infections at ICU. Antiinfect Drugs Chemother 1997;15:65-70
33. Tonelli F. Meropenem (Merrem®) vs imipenem/cilastatin for the hospital treatment of intrabdominal infections. A multicenter study. Minerva Chir 1997;52:317-26
34. Bodman K-F. Meropenem versus imipenem/cilastatin in the treatment of severe infections in intensive care units. Wien Klin Wochenschr 1999;111(Suppl 1):11
35. Pozzi A, Cravarezza P, Sleiman L. Meropenem versus imipenem/cilastatin in the treatment of community-acquired pneumonia in elderly patients. Clin Microbiol Infect 1999;5(Suppl 3):157
36. Kuo B I-T, Fung C-P, Liu C-Y. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients. Chin Med J (Taipei) 2000;63:361-7
37. Mézáros J, Michalak G, Kosieradzki M. Carbapenems in the treatment of septic surgical complications. Clin Microbiol Infect 2000;6(Suppl 1):138-9
38. Verwaest C. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect 2000;6:294-302
39. Hou F, Wu G, Zheng B. A randomised, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections. Chin J Intern Med 2001;40:589-93
40. Song Y-M, Zhao J-J, Sun L. Clinical study on meropenem and imipenem/cilastatin in treatment of respiratory tract infections. Chin Pharm J 2001;36:128-9
41. Hou F, Li J, Wu G, et al. A randomised, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections. Chin Med J 2002;115:1849-54
42. Romanelli G, Cravarezza P, Pozzi A, et al. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalised elderly patients: a comparative study against standard therapy. J Chemother 2002;14:609-17
43. Lami JLL, Wilson SEW, Hopkins JAH. Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems. Am Surg 1991;57:769-74
44. Hara K, Sakamoto A, Komori K, et al. A comparative study of meropenem and imipenem/cilastatin sodium in chronic respiratory tract infections. Chemother [Tokyo] 1992;40:1343-64
45. Nichols RL, Smith JW, Geckler RW, Wilson SE. Meropenem versus imipenem/cilastatin in the treatment of hospitalised patients with skin and soft tissue infections. South Med J 1995;88:397-404
46. Shah PM, Heller A, Fuhr HG, et al. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients. Infection 1996;24:480-4
47. Basoli A, Meli EZ, Mazzocchi P, Speranza V. Imipenem/cilastatin (1.5mg daily) versus meropenem (3g daily) in patients with intra-abdominal infections: results of a prospective, randomised, multicentre trial. Scand J Infect Dis 1997;29:503-8
48. Maggioni P, Di Stefano F, Facchini V, et al. Treatment of obstetric and gynaecologic infections with meropenem: comparison with imipenem/cilastatin. J Chemother 1998;10:114-21
49. Bartoloni A, Strohmeyer M, Corti G, et al. Multicentre randomised trial comparing meropenem (1.5g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Drugs Exp Clin Res 1999;25:243-52
50. Zanetti G, Harbarth SJ, Trampuz A, et al. Meropenem (1.5g/day) is as effective as imipenem/cilastatin (2g/day) for the treatment of moderately severe intra-abdominal infections. Int J Antimicrob Agents 1999;11:107-13
51. Xiao-Ju L, Nan X, Jia M, et al. A randomised controlled trial on meropenem versus imipenem/cilastatin in the treatment of bacterial infection. Chin J Antibiot 2001;26:118-22
52. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74
53. Crowley P. Corticosteroids prior to preterm delivery. In: Neilson JP, Crowther CA, Hodnett ED, Hofmeyr GJ, editors. The Cochrane library, issue 1. Oxford: Update Software; 1998
54. Smyth ETM, Barr JG, Hogg GM. An assessment of hidden costs on total prescribing costs of courses of meropenem and imipenem/cilastatin. Br J Med Econ 1996;10:325-40
55. Plumridge RJ. Cost analysis of infusion versus injection delivery of imipenem/cilastatin and meropenem. Clin Drug Invest 1997;14:132-6